V-Bio Ventures is an independent venture capital firm that specialises in building and financing young, innovative life science companies.
V-Bio Fund 2 has attracted several investors, including institutional investors, academic funds and family offices. It is the successor fund of V-Bio Fund 1. The second fund’s main goal is to create new companies which contribute to society through effective healthcare or sustainable agriculture.
The Eubelius team consisted of Lars Van Bever, Thomas Donnez, Michiel Stuyts and Odile Watté.
For more information, see the press release in De Tijd (Dutch) or L’Echo (French).
